Literature DB >> 27239107

Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association.

Mariabeatrice Principi1, Nicoletta Cassano1, Antonella Contaldo1, Andrea Iannone1, Giuseppe Losurdo1, Michele Barone1, Mario Mastrolonardo1, Gino Antonio Vena1, Enzo Ierardi1, Alfredo Di Leo1.   

Abstract

Inflammatory bowel disease (IBD) could be associated with several extra-intestinal manifestations (EIMs) involving musculoskeletal, hepatopancreatobiliary, ocular, renal, and pulmonary systems, as well as the skin. In the last years, hidradenitis suppurativa (HS) is acquiring an increasing interest. IBD, especially Crohn's disease (CD), is among the most reported associated diseases in HS patients. The aim of this paper is to give a brief overview of data showing a possible epidemiologic and pathogenetic association between IBD and HS. We performed a pooled-data analysis of four studies and pooled prevalence of HS in IBD patients was 12.8%, with a 95%CI of 11.7%-13.9%. HS was present in 17.3% of subjects with CD (95%CI: 15.5%-19.1%) and in 8.5% of UC patients (95%CI: 7.0%-9.9%). Some items, especially altered immune imbalance, are generally involved in IBD pathogenesis as well as invoked by HS. Smoking is one of the most relevant risk factors for both disorders, representing a predictor of their severity, despite, actually, there being a lack of studies analyzing a possible shared pathway. A role for inheritance in HS and CD pathogenesis has been supposed. Despite a genetic susceptibility having been demonstrated for both diseases, further studies are needed to investigate a genetic mutual route. Although the pathogenesis of IBD and HS is generally linked to alterations of the immune response, recent findings suggest a role for intestinal and skin microbiota, respectively. In detail, the frequent finding of Staphylococcus aureus and coagulase-negative staphylococci on HS cutaneous lesions suggests a bacterial involvement in disease pathogenesis. Moreover, microflora varies in the different cutaneous regions of the body and, consequently, two different profiles of HS patients have been identified on these bases. On the other hand, it is well-known that intestinal microbiota may be considered as "the explosive mixture" at the origin of IBD despite the exact relationship having not been completely clarified yet. A better comprehension of the role that some bacterial species play in the IBD pathogenesis may be essential to develop appropriate management strategies in the near future. A final point is represented by some similarities in the therapeutic management of HS and IBD, since they may be controlled by immunomodulatory drugs. In conclusion, an unregulated inflammation may cause the lesions typical of both HS and IBD, particularly when they coexist. However, this is still a largely unexplored field.

Entities:  

Keywords:  Crohn’s disease; Hydradenitis suppurativa; Immunosuppressant drugs; Inflammatory bowel disease; Intestinal microbiota; Skin microbiota; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27239107      PMCID: PMC4873873          DOI: 10.3748/wjg.v22.i20.4802

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  74 in total

1.  Questionnaire-based diagnosis of hidradenitis suppurativa: specificity, sensitivity and positive predictive value of specific diagnostic questions.

Authors:  S Esmann; D N Dufour; G B E Jemec
Journal:  Br J Dermatol       Date:  2010-01-17       Impact factor: 9.302

2.  Hidradenitis suppurativa and Crohn's disease in two families: a significant association?

Authors:  C Gower-Rousseau; V Maunoury; J F Colombel; P Coulom; F Piette; A Cortot; J C Paris
Journal:  Am J Gastroenterol       Date:  1992-07       Impact factor: 10.864

Review 3.  Inflammatory bowel disease: clinical aspects and established and evolving therapies.

Authors:  Daniel C Baumgart; William J Sandborn
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

Review 4.  Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.

Authors:  Maiwand Nazary; H H van der Zee; E P Prens; Gert Folkerts; Jurr Boer
Journal:  Eur J Pharmacol       Date:  2011-09-14       Impact factor: 4.432

Review 5.  Hidradenitis suppurativa: the role of immune dysregulation.

Authors:  Genevieve Kelly; Cheryl M Sweeney; Anne-Marie Tobin; Brian Kirby
Journal:  Int J Dermatol       Date:  2014-06-25       Impact factor: 2.736

Review 6.  Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.

Authors:  Pia Haslund; Robert A Lee; Gregor B E Jemec
Journal:  Acta Derm Venereol       Date:  2009-11       Impact factor: 4.437

Review 7.  Hidradenitis suppurativa.

Authors:  F William Danby; Lynette J Margesson
Journal:  Dermatol Clin       Date:  2010-10       Impact factor: 3.478

8.  Estrogen sulfotransferase is expressed in subcutaneous adipose tissue of obese humans in association with TNF-alpha and SOCS3.

Authors:  Rexford S Ahima; Takara L Stanley; Victor K Khor; Markella V Zanni; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2011-05-04       Impact factor: 5.958

9.  Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology.

Authors:  Bodo C Melnik; Gerd Plewig
Journal:  Exp Dermatol       Date:  2013-03       Impact factor: 3.960

Review 10.  Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis.

Authors:  Ryan Ungaro; Charles N Bernstein; Richard Gearry; Anders Hviid; Kaija-Leena Kolho; Matthew P Kronman; Souradet Shaw; Herbert Van Kruiningen; Jean-Frédéric Colombel; Ashish Atreja
Journal:  Am J Gastroenterol       Date:  2014-09-16       Impact factor: 10.864

View more
  9 in total

Review 1.  Impact of gut microbiota on gut-distal autoimmunity: a focus on T cells.

Authors:  Maran L Sprouse; Nicholas A Bates; Krysta M Felix; Hsin-Jung Joyce Wu
Journal:  Immunology       Date:  2019-01-21       Impact factor: 7.397

Review 2.  [Cutaneous involvement in chronic inflammatory bowel disease : Crohn's disease and ulcerative colitis].

Authors:  L Richter; K Rappersberger
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

3.  Acute fatty liver of pregnancy in a woman with ulcerative colitis and familial hidradenitis suppurativa.

Authors:  Adam Morton
Journal:  Obstet Med       Date:  2017-11-19

Review 4.  Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.

Authors:  John W Frew; Jason E Hawkes; James G Krueger
Journal:  Ther Adv Chronic Dis       Date:  2019-03-01       Impact factor: 5.091

5.  Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM).

Authors:  Monique Capron; Laurent Béghin; Céline Leclercq; Julien Labreuche; Arnaud Dendooven; Annie Standaert; Marie Delbeke; Adeline Porcherie; Maria Nachury; Arnaud Boruchowicz; Jean-Louis Dupas; Mathurin Fumery; Thierry Paupard; Sylviane Catteau; Dominique Deplanque; Jean-Frederic Colombel; Pierre Desreumaux
Journal:  J Clin Med       Date:  2019-12-24       Impact factor: 4.241

Review 6.  How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease.

Authors:  Viviana Laredo; Carla J Gargallo-Puyuelo; Fernando Gomollón
Journal:  J Clin Med       Date:  2022-02-04       Impact factor: 4.241

Review 7.  Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases.

Authors:  Md Rayhan Mahmud; Sharmin Akter; Sanjida Khanam Tamanna; Lincon Mazumder; Israt Zahan Esti; Sanchita Banerjee; Sumona Akter; Md Rakibul Hasan; Mrityunjoy Acharjee; Md Sajjad Hossain; Anna Maria Pirttilä
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 8.  Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations.

Authors:  Cristina Bezzio; Cristina Della Corte; Marta Vernero; Imma Di Luna; Gianpiero Manes; Simone Saibeni
Journal:  Therap Adv Gastroenterol       Date:  2022-07-28       Impact factor: 4.802

Review 9.  Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Mark Fleisher; Jan Marsal; Scott D Lee; Laura E Frado; Alyssa Parian; Burton I Korelitz; Brian G Feagan
Journal:  Dig Dis Sci       Date:  2018-02-26       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.